India’s third-largest pharmaceutical company by revenue, Cipla, is up for grabs in a three-way fight between Torrent Pharmaceuticals, Dr. Reddy’s Laboratories (DRL) and private equity (PE) giant Blackstone.
Analysts say
Cipla on the block: Who's a better fit and what it means for shareholders?
As per IIFL Securities, Cipla with a dominating market share of 7% and 23% in acute therapies like respiratory and anti-infectives, respectively, would strengthen Torrent's position in these
 "Cipla")
Web Exclusive Premium
Listen to This Article
Topics : Stock Market Cipla Dr Reddy's Torrent Pharma M&A acquisition
First Published: Sep 13 2023 | 12:44 PM IST
Key stories on business-standard.com are available only to BS Premium subscribers.
Register to read more on Business-Standard.com
